Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2015; 5(4): 107-114


Acute and Sub-acute oral toxicity studies of Deedan-A Unani drug in Albino rats

Showkat A. Dar, Khalid Ghazanfar, Seema Akbar, Akbar Masood, Tazeen Nazir, Khalid M. Siddiqui, Pawan Kumar.




Abstract

Abstract.
Deedan is a very effective compound formulation of Unani System of medicine used for the treatment of worm infestation. The objective of this study was to investigate the Acute and Sub-acute toxicity of Deedan in Albino of both the sexes. In the acute toxicity study, Deedan was administered orally at the limit dose of 2000mg/kg b.w. to both male and female rats, and the animals were then observed individually 30 minutes, 4 hour post-doing, and at least once daily for next 14 days. In the Sub-acute toxicity study a limit dose of 1000 mg/kg body weight was administered orally in a single bolus everyday for 28 days. The rats were observed daily during the period of the study, and sacrificed on the 29th day. Observation parameters of the animals included a comparative evaluation of general appearance/behaviour, morbidity/mortality, body weights, food/water consumption, and haematology, biochemistry and histopathology of major organs of treated and control groups. There was no mortality, morbidity, or cage-side/laboratory findings of any adverse health effect in the treated animals in comparison to their respective controls in both toxicity studies. Deedan was thus found to be free of any toxic effects under the conditions of these studies.

Key words: Acute toxicity; subacute toxicity; Deedan; triglycerides; histopathology






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.